Teladoc Health reported Q4 2024 revenue of $640.5 million, flat QoQ and down 3.0% year over year, with gross profit of $451.6 million and a gross margin of 70.5%. The company posted an operating loss of $48.2 million and a net loss of $48.4 million, translating to an EPS of -$0.28. EBITDA reached $11.8 million, yielding an EBITDA margin of roughly 1.8%. Notwithstanding the negative GAAP profitability, Teladoc generated positive operating cash flow of $85.9 million and free cash flow of $56.3 million, supported by favorable working capital movements and depreciation/al compensation. Cash at end of period stood at $1.299 billion, with total debt of $1.585 billion and net debt of $286 million, leaving the balance sheet relatively liquid for ongoing investments and debt service.